Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4] - The acquisition of Renergen is nearing completion, with all but one regulatory approval received, expected imminently [5] - The first quantum enrichment plant is producing ytterbium-176, with commercial quantities expected in the first half of 2026 [7] Market Data and Key Metrics Changes - The company has secured contracts for silicon-28 and is looking to satisfy all current customer orders in 2026 [4] - The acquisition of Skyline Builders aims to secure supply chains of critical materials essential to the U.S. and ASP Isotopes [21] Company Strategy and Development Direction - The company is focused on expanding its isotope enrichment capabilities and has plans for multiple new production facilities [8][28] - Quantum Leap Energy aims to stabilize the nuclear supply chain and is developing technologies for lithium-7 and HALEU production [12][18] - The company is also investing in radiopharmaceutical operations, with plans to expand into the U.S. market [11][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational progress and customer relationships, emphasizing the importance of completing phase 1C for de-risking projects [39] - The company anticipates significant revenue opportunities in 2026 and 2027, particularly around ytterbium-176 and silicon-28 [49] - Management acknowledged the complexities of the isotope industry and the need for transparency with investors regarding future projections [50][52] Other Important Information - The company is preparing for the IPO of Quantum Leap Energy, with S-1 documentation filed with the SEC [13][27] - The company plans to begin construction of new plants in various locations, including Iceland, the U.S., and the U.K. during 2026 [28] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of starting up the plant and modifications agreed upon with customers, but operations are currently going well [37] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Expected by the end of the first quarter, focusing on completing phase 1C [39] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue from carbon is expected to ship by the end of December, with silicon isotopes expected to generate revenue in 2026 [41] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers are satisfied with the results of the samples, indicating that the technology works [43][47] Question: Is the $50-$70 million revenue opportunity in 2026 and 2027 still valid? - The company is not changing previous guidance and will provide updates as more clarity is achieved [49][53] Question: Can you help us understand the capital commitment in 2026 for new facilities? - Detailed breakdowns will be provided in future updates, but specifics are not available at this time [54][55] Question: Can you talk about the opportunity for LEU Plus? - LEU Plus is a subcategory of HALEU, driven by customer inquiries, and is expected to enhance power density and extend refueling cycles for existing plants [58][60] Question: Should we model the $3 million revenue from Skyline Builders going forward? - This revenue is not expected to continue, as the focus will shift away from construction activities [63]

This presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and ...

Core Insights - IsoBio, Inc. is focused on developing a pipeline of monoclonal antibody-based radioisotope therapeutics targeting both derisked and novel tumor antigens for cancer treatment [1][3] - The company has successfully closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. [1][3] Company Overview - IsoBio is a U.S.-based radiotherapeutic development company that specializes in antibody-isotope conjugates (AICs) [1][12] - The company plans to establish offices in Seattle, WA, and Gladwyne, PA [2][6] - IsoBio's management team is led by Bruce Turner, M.D., Ph.D., who has extensive experience in the biotech industry [6][7] Strategic Collaboration - IsoBio has formed a strategic partnership with ASP Isotopes Inc. and its nuclear medicine subsidiary, PET Labs, to enhance manufacturing capabilities and reduce supply chain uncertainties for isotopes [2][4] - This collaboration aims to leverage ASP Isotopes' technology and global manufacturing capabilities to develop novel isotopes for radiotherapeutics [2][4] Product Development - IsoBio is developing radiotherapeutics that include Lutetium-177, Actinium-225, Terbium-161, and other undisclosed novel radioisotopes [5] - The company utilizes proprietary linker and conjugation technology to create highly potent AICs, which provide targeted treatment for difficult-to-treat tumors [5][12] Market Context - The supply chain for radiotherapeutics has faced challenges due to limited availability of commonly used isotopes, making IsoBio's strategic partnership advantageous [4] - There is a growing demand for innovative cancer therapies, and IsoBio's focus on targeted therapies aligns with this market need [3][4]

Core Viewpoint - ASP Isotopes Inc. has announced a registered direct offering of 7,500,000 shares at $8.00 per share, aiming to raise approximately $60.0 million in gross proceeds [1][2]. Group 1: Offering Details - The offering is expected to close on or about July 25, 2025, pending customary closing conditions [1]. - Cantor and Canaccord Genuity are acting as joint book-running managers, while Ocean Wall Limited serves as the financial advisor for the offering [2]. - The net proceeds will be utilized for general corporate purposes, including working capital, operating expenses, and capital expenditures [2]. Group 2: Company Overview - ASP Isotopes Inc. is a development stage advanced materials company focused on producing isotopes for various industries, employing proprietary Aerodynamic Separation Process (ASP technology) [5]. - The company aims to produce highly enriched isotopes for healthcare and technology sectors, and plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology [5]. - The company has isotope enrichment facilities located in Pretoria, South Africa, dedicated to enriching light isotopes [5]. Group 3: Market Demand - There is an increasing demand for isotopes such as Silicon-28 for quantum computing and various isotopes for emerging healthcare applications and green energy applications [6]. - The ASP technology is particularly suitable for enriching both low and heavy atomic mass molecules, aligning with the growing market needs [6].

Core Viewpoint - ASP Isotopes Inc. is proposing a secondary listing of its common stock on the Johannesburg Stock Exchange (JSE) while maintaining its listing on the Nasdaq Capital Market, aiming to enhance liquidity and diversify its shareholder base [1][3][4]. Company Overview - ASP Isotopes Inc. is an advanced materials company focused on developing technology and processes for isotope production, with a strong emphasis on healthcare and technology industries [6]. - The company employs proprietary Aerodynamic Separation Process (ASP technology) for isotope enrichment and has facilities in Pretoria, South Africa [6][7]. Strategic Rationale for JSE Listing - The JSE listing is expected to provide access to a deeper capital market, enhance liquidity for shareholders, and attract interest from South African institutional investors due to the company's local presence and specialized technologies [3][4]. - The company has a significant South African footprint, with 97% of its employees and all operating assets located in South Africa, highlighting its commitment to the local community [5]. Market Demand and Product Focus - There is a growing demand for isotopes such as Silicon-28 (Si-28) for quantum computing and various isotopes for emerging healthcare and green energy applications [7]. - ASP Isotopes plans to enrich isotopes for the nuclear energy sector using its developing Quantum Enrichment technology [6].

Core Insights - ASP Isotopes Inc. is undergoing a strategic separation of its Nuclear Fuels Business and Specialist Isotope Products into two independent companies, with plans to complete this by the second half of 2025 [2][5][8] - Mr. Sipho Maseko has joined the board of directors of ASP Isotopes, bringing extensive experience from his previous roles in telecommunications and industrial sectors [1][3][4] - Dr. Hendrik Strydom has transitioned from the board of directors of ASP Isotopes to the board of managers of Quantum Leap Energy LLC, focusing on advanced nuclear fuel production [2][6][7] Company Developments - The separation will involve a spin-out of Quantum Leap Energy LLC, which aims to develop advanced nuclear fuels such as HALEU and Lithium-6, and will become a separate public company [5][8] - The board of directors is evaluating the optimal composition for the board of managers of Quantum Leap Energy LLC, with Dr. Strydom now part of this team [6][7] - The company is committed to maximizing shareholder value during the separation process and will consider various options to achieve this [8] Leadership and Expertise - Mr. Maseko has a strong background in various industries, including telecommunications and energy, and has been instrumental in advancing ASP Isotopes' business in South Africa [3][4] - Dr. Strydom has a 40-year career in isotope enrichment and has previously worked on nuclear fuel programs, enhancing the company's technical capabilities [6][7] Market Focus - ASP Isotopes is dedicated to producing isotopes for multiple industries, including healthcare and technology, and is developing proprietary technologies for isotope enrichment [10][11] - There is a growing demand for isotopes in emerging applications, particularly in quantum computing and green energy, which the company aims to address [11]

Financial Data and Key Metrics Changes - The fourth quarter results met expectations with PET Labs generating $4.2 million in revenue for the year, indicating stability in the business [4] - The company has not provided guidance for the current year or the first quarter, focusing instead on the startup of three manufacturing plants for commercial production [5][6] Business Line Data and Key Metrics Changes - The Carbon-14 plant faced feedstock issues but is now enriching Carbon-14 after receiving necessary materials [5] - The Silicon-28 plant encountered commissioning challenges but has been successfully repaired and is operational [6][7] - Ytterbium-176 has started commercial enrichment after overcoming technical difficulties with equipment [9] Market Data and Key Metrics Changes - Expected production for Ytterbium is around one kilogram per year, with a projected price of $20,000 per gram [19] - Carbon-14 has a take-or-pay contract with a minimum of $2.5 million annually, with potential for higher revenue [19] - PET Labs is expected to grow revenue from $4 million last year due to significant investments [21] Company Strategy and Development Direction - The company plans to construct additional plants for Nickel-64, Gadolinium-160, and Lithium-6, with construction timelines dependent on regulatory approvals [22][24] - There are ambitions to expand manufacturing capabilities in North America through partnerships to navigate regulatory challenges [29][30] - The company aims to build more isotope enrichment facilities in various regions to enhance its market presence [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving cash flow breakeven in the second half of the year, supported by a strong balance sheet [55] - Regulatory discussions with the South African government are progressing positively, with plans to start production in the second half of the year [69][81] - The company is focused on addressing regulatory and licensing challenges to expedite plant construction and operations [68][70] Other Important Information - The company has received significant interest in Ytterbium-176, with two kilograms of indicated demand from customers [38] - Management highlighted the importance of securing supply agreements before finalizing contracts for Ytterbium [36] - The company is actively working on enhancing sell-side coverage to improve market perception [87] Q&A Session Summary Question: What are your expected revenues for ASPI in 2025? - The company has not provided specific guidance but indicated that signed contracts can help estimate an annualized run rate [18] Question: Can you provide guidance on the timing of the construction of new plants? - Construction timelines depend on obtaining export permits, which are currently in process [24] Question: When do you expect to start enriching product in Pelindaba? - The timeline is contingent on regulatory approval, with hopes to begin this year [81] Question: How are market prices changing for the isotopes? - Carbon-14 is fixed at $24,000 per gram, while Ytterbium is facing push-back at $20,000 per gram, and Silicon-28 may see a price reduction to stimulate demand [82][84] Question: Are there any updates on the QLE spinout? - The company is working on necessary permits and documentation for the spinout, with no specific timeline provided [35][33] Question: What keeps management awake at night now that production has started? - Competing against government-backed entities remains a concern, particularly regarding capital costs for building plants [120]

Financial Data and Key Metrics Changes - The fourth quarter results met expectations with PET Labs generating $4.2 million in revenue for the year, indicating stability in the business [4] - The company has not provided guidance for the current year or the first quarter, focusing instead on the startup of three manufacturing plants for commercial production [5][6] Business Line Data and Key Metrics Changes - The Carbon-14 plant faced feedstock issues but is now enriching Carbon-14 after receiving necessary materials [5] - The Silicon-28 plant encountered commissioning challenges but has been successfully repaired and is operational [6][7] - Ytterbium-176 has started commercial enrichment after overcoming technical difficulties with equipment [9] Market Data and Key Metrics Changes - Expected production for Ytterbium is around one kilogram per year, with a projected price of $20,000 per gram [19] - Carbon-14 has a take-or-pay contract with a minimum of $2.5 million annually, with potential for higher revenue [19] - PET Labs generated $4 million last year, with expectations for growth due to recent investments [21] Company Strategy and Development Direction - The company plans to construct additional plants for Nickel-64, Gadolinium-160, and Lithium-6, with construction timelines dependent on regulatory approvals [22][24] - There are ambitions to expand manufacturing capabilities in North America through partnerships to navigate regulatory challenges [29][30] - The company aims to build more isotope enrichment facilities in various regions to enhance its market presence [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving cash flow breakeven in the second half of the year, supported by a strong balance sheet [55] - Regulatory discussions with the South African government are progressing positively, with plans to start production at Pelindaba [68][81] - The company is actively engaging with potential U.S. partners, including TerraPower, to enhance its market position [61] Other Important Information - The company has seen a significant increase in headcount from approximately 130 to 150, with plans for further selective hiring [78] - Management is focused on improving financial reporting processes to ensure timely results [94] Q&A Session Summary Question: What are your expected revenues for ASPI in 2025? - The company has not provided specific guidance but indicated that signed contracts can help estimate an annualized run rate [18] Question: Can you provide guidance on the timing of the construction of new plants? - Construction timelines depend on obtaining necessary export permits, with the first plant expected to come online later this year [22][24] Question: What is the current status of the QLE spinout? - The spinout is contingent on securing a location for the uranium plant and achieving cash flow breakeven [33][35] Question: How are market prices changing for the isotopes? - Carbon-14 is fixed at $24,000 per gram, while Ytterbium is facing push-back at $20,000 per gram, and Silicon-28 may see a price reduction to stimulate demand [82][84] Question: Are there any new emerging competitors in the market? - Currently, there are no significant new competitors identified in the market for the isotopes being produced [96] Question: What keeps management awake at night now that production has started? - Competing against government-backed entities remains a concern, particularly regarding capital costs for building plants [119]